医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PerkinElmer Launches Innovative High Throughput Imaging System for Clearer and Faster Visualization of Disease Markers in Tissue

2014年03月01日 AM06:40
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of the Lamina multilabel slide scanner at the USCAP 2014 Annual Meeting. The Lamina scanner is a high throughput imaging system designed to help research pathologists to more easily study protein expression and the relationships between disease markers in formalin-fixed, paraffin-embedded (FFPE) tissue sections. This allows research pathologists to gain a deeper understanding of diseases for the development of more effective therapies and treatments.

Configured to meet the needs of a larger research facility, the Lamina scanner includes high-speed brightfield and fluorescence imaging modalities along with PerkinElmer’s proprietary Autofluorescence Reduction Technology (ART™). It is designed to reduce interference from autofluorescence — an unwanted by-product of tissue fixation — and fluorophore cross-talk, in which the signal from one fluorophore bleeds into multiple channels. Both of these effects obscure real signals, which can result in an incorrect assessment of a slide. The Lamina scanner delivers these improvements in real-time during whole-slide scanning, enabling clearer visualization of protein biomarker expression in fluorescently labeled tissues. As a result, the Lamina scanner allows users to obtain more accurate information from histological specimens.

“As a leading provider of imaging platforms for disease research, PerkinElmer routinely engages research pathologists globally so we can better understand the complexities of studying disease markers and develop innovative solutions to meet their needs,” said Jim Corbett, President, Diagnostics / Life Sciences & Technology, PerkinElmer. “The Lamina scanner can help research pathologists more effectively interpret their images by automating workflows and providing clearer and faster results. These advanced digital pathology capabilities can help lead to a better understanding of disease.”

The Lamina scanner produces exceptional-quality, digital, whole-slide images of hematoxylin and eosin, (H&E) immunohistochemistry (IHC) and immunofluorescence-labeled tissue sections and tissue microarrays (TMAs), which can be stored and shared electronically without degradation. The Lamina scanner complements PerkinElmer’s comprehensive portfolio of quantitative pathology solutions for translational research, which includes the Vectra® and Nuance® Multispectral imaging systems, inForm® Advanced Image Analysis Software, and biomarker reagent platforms.

For more information on the Lamina scanner, please visit our website or the PerkinElmer booth #216 at USCAP on March 3-5.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140228005765/en/

CONTACT

PerkinElmer, Inc.
Brian Willinsky, +1 781-663-5728
brian.willinsky@perkinelmer.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表